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Abstract: Recent studies indicate that selective noradrenergic (atomoxetine) and serotonergic (citalopram)
reuptake inhibitors may improve response inhibition in selected patients with Parkinson’s disease, restor-
ing behavioral performance and brain activity. We reassessed the behavioral efficacy of these drugs in a
larger cohort and developed predictive models to identify patient responders. We used a double-blind
randomized three-way crossover design to investigate stopping efficiency in 34 patients with idiopathic
Parkinson’s disease after 40 mg atomoxetine, 30 mg citalopram, or placebo. Diffusion-weighted and func-
tional imaging measured microstructural properties and regional brain activations, respectively. We con-
firmed that Parkinson’s disease impairs response inhibition. Overall, drug effects on response inhibition
varied substantially across patients at both behavioral and brain activity levels. We therefore built binary
classifiers with leave-one-out cross-validation (LOOCV) to predict patients’ responses in terms of
improved stopping efficiency. We identified two optimal models: (1) a “clinical” model that predicted
the response of an individual patient with 77–79% accuracy for atomoxetine and citalopram, using clini-
cally available information including age, cognitive status, and levodopa equivalent dose, and a simple
diffusion-weighted imaging scan; and (2) a “mechanistic” model that explained the behavioral response
with 85% accuracy for each drug, using drug-induced changes of brain activations in the striatum and
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presupplementary motor area from functional imaging. These data support growing evidence for the
role of noradrenaline and serotonin in inhibitory control. Although noradrenergic and serotonergic drugs
have highly variable effects in patients with Parkinson’s disease, the individual patient’s response to
each drug can be predicted using a pattern of clinical and neuroimaging features. Hum Brain Mapp
37:1026–1037, 2016. VC 2016 The Authors Human Brain Mapping Published by Wiley Periodicals, Inc.
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INTRODUCTION
There is increasing interest in the development of strati-
fied medicine in neurology and psychiatry, driven by the
recognition of patient-to-patient heterogeneity in clinical
symptoms and treatment responses [Matthews et al., 2014;
Schumann et al., 2014; Stephan et al., 2015]. Indeed, the
heterogeneity of patients may lead to false-negative results
in clinical trials that rely solely on unselected groups or
nonstratified therapies [Sperling et al., 2011; Wardlaw
et al., 2014]. The objective of patient stratification is to
identify likely responders from nonresponders to maxi-
mize the likely efficacy and cost-effectiveness of a given
treatment. Typically it uses demographic and clinical
measures but these may be combined with biomarkers
such as brain imaging or genotype. In this study, we
aimed to build predictive models to identify patient
responders in the context of Parkinson’s disease, examin-
ing the potential of novel noradrenergic and serotonergic
therapies for impulsivity.
Previous research has demonstrated that selective nor-
adrenaline (atomoxetine) and serotonin (citalopram) reup-
take inhibitors can improve response inhibition in a
subgroup of patients with Parkinson’s disease. Behavioral
performance, brain activity, and/or connectivity were par-
tially restored at either a group level or in a subgroup of
patients [Kehagia et al., 2014; Ye et al., 2014, 2015], rein-
forcing preclinical evidence that these drugs enhance the
neural systems for inhibitory control. Here we take a step
further to predict the behavioral impact of the drugs in a
larger patient cohort, using basic clinical and imaging
measures. However, the approach is not limited to these
drugs or to Parkinson’s disease, but could be implemented
in other clinical trials.
In Parkinson’s disease, impulsivity is a problem of not
only the impulse control disorders present in about 14% of
patients [Weintraub et al., 2010]. It occurs even in patients
without impulse control disorders [Nombela et al., 2014a;
Obeso et al., 2011a]. The inability to stop an action is one
of the several dimensions of impulsivity, along with
abnormal choices under risk and uncertainty in gambling,
delay intolerance, and willingness to respond with insuffi-
cient information. This study focuses on response inhibi-
tion, in part because of the wealth of animal studies and
patient data using response inhibition tasks, and because
the potential benefit of atomoxetine has been shown to
generalize to other forms of impulsivity [Kehagia et al.,
2014].
Response inhibition has been widely studied using the
stop-signal reaction time (SSRT) task in Parkinson’s dis-
ease and other brain disorders [Cubillo et al., 2014a; Gaug-
gel et al., 2004; Luijten et al., 2013; Obeso et al., 2011a;
Verbruggen et al., 2013]. Compared to healthy adults,
patients with Parkinson’s disease have longer SSRT,
reflecting difficulty in cancelling a motor response. The
SSRT correlates with ecological and other laboratory meas-
ures of impulsivity [Kehagia et al., 2014; Nombela et al.,
2014a], with the added advantage that it enables both
functional imaging of humans and direct comparison to
animal models.
We hypothesized that response inhibition deficits in Par-
kinson’s disease result from loss of noradrenergic and
serotonergic projections to the forebrain [Goldstein et al.,
2011; Politis et al., 2010], exacerbated by pathological
changes in the white matter of frontostriatal circuits that
extend from the frontal gyri via the anterior limb of the
internal capsule to the basal ganglia [Duncan et al., 2015;
Koshimori et al., 2015; Rae et al., 2012; Zheng et al., 2014].
Although dopaminergic dysfunction is a canonical feature
of Parkinson’s disease and directly linked to impulse con-
trol disorders such as pathological gambling [Ray and
Strafella, 2013], levodopa withdrawal studies in patients
and selective dopaminergic treatments in animal models
indicate minimal effects of dopamine on stop-signal
response inhibition [Bari and Robbins, 2013; Obeso et al.,
2011b]. In contrast, animal and human studies indicate
noradrenergic and serotonergic regulation of response
inhibition [Aston-Jones and Cohen, 2005; Eagle et al., 2008;
Robbins, 2007]. For example, atomoxetine and citalopram
improve performance on motor inhibition tasks [Chamber-
lain et al., 2006], reduce premature decisions [Baarendse
et al., 2013; Broos et al., 2012], and enhance the associated
frontal cortical activations [Chamberlain et al., 2009; Del-
Ben et al., 2005; Macoveanu et al., 2013]. However, the
behavioral effects of atomoxetine and citalopram depend
on individual differences in the baseline state of noradren-
ergic and serotonergic systems [Robinson et al., 2008; Ye
et al., 2014, 2015] which may be one reason why unstrati-
fied studies yield negative results.
This study aimed to identify clinical and imaging fea-
tures which could enable an accurate prediction of the
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behavioral effect of atomoxetine (40 mg) and citalopram
(30 mg) on response inhibition in Parkinson’s disease. We
used each drug in addition to standard dopaminergic ther-
apy, in anticipation of a clinical role as adjunctive therapy
for nonmotor symptoms rather than substitution of levo-
dopa. We combined the stop-signal task, pharmacological
intervention, brain imaging, and machine learning to
develop two models. First, a “clinical” predictive model
that indicates whether clinically available information,
including demographic measures (e.g., age), clinical meas-
ures (e.g., disease severity, cognitive status, levodopa equiv-
alent dose), and a simple baseline diffusion-weighted
imaging measure, is sufficient to predict a patient’s
response to treatment. We emphasize that such a model is
not in lieu of a clinical trial, which would require both
chronic treatments and clinical outcome measures, but
serves to illustrate the potential for patient stratification in
future trials. Second, we developed a post-hoc “mechanistic”
model that indicates whether behavioral effects can addi-
tionally be explained by changes of frontal and striatal acti-
vations as measured from functional brain imaging. The
advantage of this second model lies in the reinforcement of
translational models of impulsivity and Parkinson’s disease.
METHODS
This study was approved by the local research ethics
committee and exempted from Clinical Trials status by the
UK Medicines and Healthcare products Regulatory Agency.
Subjects
Thirty-four patients with idiopathic Parkinson’s disease
(UK PD Society Brain Bank Diagnostic Criteria) and 42
healthy control subjects with no history of significant neuro-
logical or psychiatric disorder participated after providing
written informed consent. Thirty-eight subjects (18 patients
with Parkinson’s disease and 20 control subjects) contributed
to previously published studies [Ye et al., 2014, 2015]. Thirty-
eight different subjects (16 patients with Parkinson’s disease
and 22 control subjects) were newly recruited and tested fol-
lowing the same research protocol. The two cohorts were
combined to increase the ability to effectively fit a predictive
model. Three patients from the second cohort had contrib-
uted to our previous published studies, and their data have
been excluded from the first cohort for the current analysis.
All subjects were right-handed. No patient had dementia
(mini mental state examination >26/30), significant current
depression, or contraindications to magnetic resonance imag-
ing (MRI), atomoxetine, or citalopram. The patients were
tested on their regular antiparkinsonian medications, includ-
ing levodopa (N 5 32), dopamine agonists (pramipexole,
ropinirole, or rotigotine; N 5 25), and other medications
(amantadine, entacapone, or rasagiline; N 5 12). Levodopa
equivalent dose was calculated according to Tomlinson et al.
[2010]. The decision to maintain usual dopaminergic medica-
tion was because of the likelihood that either new treatment
would be adjunctive to dopaminergic therapy. Table I sum-
marizes the demographic and clinical data.
We screened the patients for impulse control disorders
(pathological gambling, hypersexuality, binge eating, and
problematic internet use) but did not restrict our subjects
to the minority (14%) of patients with impulsive/compul-
sive disorders, because response inhibition deficits and
impulsivity exist in the general population of patients with
Parkinson’s disease. Indeed, no patient declared symptoms
or behaviors indicative of an impulse control disorder.
Note that the Questionnaire for Impulsive–Compulsive
Disorders in Parkinson’s Disease Rating Scale screening
tool had not been validated when the study protocol was
developed and therefore was not used.
Experimental Design
The study used a double-blind randomized placebo-
controlled three-way crossover design. The patients attended
TABLE I. Mean demographic and clinical measures (standard deviations) and group differences
Measures Patienta Control
Group
differenceb
Sex ratio (male:female) 21:13 23:19 ns
Age (years) 66.5 (7.0) 66.6 (6.9) ns
Education (years) 12.5 (5.7) 14.7 (2.8) ns
Mini mental state examination 28.6 (1.6) 29.3 (1.0) ns
Duration of symptoms (years) 8.9 (6.3) – –
Unified Parkinson’s Disease Rating Scale
(section III motor subscale)
22.5 (7.8) – –
Hoehn and Yahr 2.0 (0.6) – –
Schwab and England activities of daily living scale 81.2 (18.5) – –
Levodopa actual dose (mg/day) 547.1 (304.0) – –
Levodopa equivalent dose (mg/day) 913.7 (522.3) – –
aPatients with Parkinson’s disease were tested on their regular dopaminergic antiparkinsonian medications.
bP-values of chi-squared or unpaired t-tests as appropriate, corrected for multiple comparisons; ns, not significant.
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separate sessions at least 6 days apart, including diffusion-
weighted and functional MRI, after 40 mg oral atomoxetine,
30 mg oral citalopram, or an identically overcoated placebo
capsule. We used a cross-over design for its advantages
over parallel-group design in a placebo-controlled study of
this scale. It controls for several potential confounders across
sessions, including individual differences in disease severity
and progression, severity and distribution of neurotransmit-
ter loss, and dopaminergic drug responsivity, in addition to
age, sex, and genetic polymorphisms. Patients were scanned
at the same time of the day on each session. The minimal
interval of 6 days between sessions minimizes pharmacolog-
ical carry-over effects in view of the short half-life of each
drug [Chalon et al., 2003; Rocha et al., 2007]. To reduce prac-
tice effects on the drug effect, we randomized the drug
order (using permutation within groups of six successive
subjects to ensure counterbalancing).
The patients were moved to the scanner for the stop-
signal task and functional imaging 2 h after the drug
administration, close to the estimated peak plasma concen-
tration of the drugs. Blood samples were collected imme-
diately before the task and imaging to monitor individual
differences in plasma drug concentration that reflects dif-
ferences in drug absorption and metabolism (see Discus-
sion). The mean plasma drug concentrations were 401.9
ng/mL after atomoxetine (range 31.7–889.0 ng/mL), 40.2
ng/mL after citalopram (6.6–70.3 ng/mL), and 0 ng/mL
after placebo. The current range of plasma drug concentra-
tion was comparable to that in previous human studies
using similar oral dose of atomoxetine [Chamberlain et al.,
2009; Kehagia et al., 2014] and citalopram [Hughes et al.,
2015]. The control subjects were tested without drug or
placebo, to provide normative data on the task and
imaging.
The stop-signal task has been described in detail else-
where [Ye et al., 2014, 2015]. In brief, it included randomly
interleaved 360 Go trials and 80 stop-signal trials. Go trials
had a left/right black arrow (1000 ms) to which subjects
responded by pressing left/right buttons with the right
hand. On stop-signal trials, the left/right black arrow
turned red, concurrent with a beep, after a short variable
delay, and subjects were required to make no response.
The stop-signal delay was adjusted from trial to trial by an
online tracking algorithm to maintain 50% successful inhi-
bition. In 40 additional trials, the stop-signal delay was set
to 0 ms (equivalent to NoGo trials).
Behavioral Data Analysis
We first replicated previous basic findings in behavior
and imaging [Ye et al., 2014, 2015] with the combined
cohort, and measured drug-induced changes in SSRT and
brain activation for each patient. We then used machine-
learning models to predict individual patients’ changes in
SSRT, using the clinical and imaging data, to discriminate
patient responders and nonresponders.
Behavioral measures of the stop-signal task included the
SSRT, mean reaction time of correct Go trials, and rate of
Go commission errors. The SSRT was estimated using the
integration method and adjusted for omission errors [Ye
et al., 2014, 2015]. Shorter SSRTs indicate better stopping
efficiency. We examined group differences on all behav-
ioral measures using two-sample t tests (PD-placebo versus
control) and the effect of each drug on SSRT separately
using repeated-measures ANCOVAs. The ANCOVA had
drug (atomoxetine/citalopram versus placebo) as a within-
subject factor and controlled for individual differences in
age, disease severity (Unified Parkinson’s Disease Rating
Scale, UPDRS, III-motor subscale), cognitive status (mini
mental state examination), levodopa equivalent dose, and
plasma drug concentration.
MRI Acquisition and Analysis
MRI was acquired in two stages on the same Siemens
Trio 3T scanner with a 12-channel headcoil (Siemens
Healthcare, Erlangen, Germany). The first 38 subjects
were tested in 2011–2012 and the second 38 subjects
were tested in 2012–2013. For all subjects, diffusion-
weighted images were collected along 63 gradient direc-
tions (single acquisition, 63 sequential ascending axial
slices, 192 3 192 mm2 field of view, 2 mm isomorphic
resolution) and analyzed with FSL4.1 following a stand-
ardized FSL pipeline (www.fmrib.ox.ac.uk/fsl). The
images were corrected for head movements and eddy
currents, and smoothed with a 2.5-mm Gaussian kernel.
Diffusion tensors were linearly fitted to the images.
Images of fractional anisotropy and mean diffusivity
were computed, adjusted for outlier values, registered to
a study-specific template (i.e., the fractional anisotropy
image of a subject that required the least transformation
to the fractional anisotropy images of all other subjects),
and normalized to the MNI152 space. Mean skeletons
were derived and thresholded at a fractional anisotropy
of >0.2 to represent the center of the white matter tracts
common to all subjects. Values of fractional anisotropy
and mean diffusivity were extracted from the skeleton-
ized anterior internal capsule of frontostriatal connec-
tions using anatomically defined masks based on the
Johns Hopkins University white-matter atlas. This region
was chosen as most relevant to our hypothesis of the
role of frontostriatal circuits [Ye et al., 2014, 2015] and in
view of the prior evidence of white matter involvement
of this region in Parkinson’s disease [Duncan et al., 2015;
Rae et al., 2012].
Functional images of the first stage used a “silent” echo
planar imaging sequence (32 sequential descending axial
slices, 2656 ms repetition time, 44 ms echo time, 788 flip
angle, 192 3 192 mm2 field of view, 3 mm thickness,
0.75 mm gap, and 3 3 3 mm2 in-plane resolution). The
silent sequence was used to create a quiet and patient-
friendly environment for a repeated-measures design to
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study the stop-signal task with auditory stimuli. However,
the quiet sequence was not optimal for image quality in
the midbrain. We therefore switched to a second sequence
at the second stage, with other acquisition parameters
adjusted accordingly. Functional images of the second
stage used a “standard” echo planar imaging sequence (32
sequential descending axial slices, 2000 ms repetition time,
30 ms echo time, 788 flip angle, 192 3 192 mm2 field of
view, 3 mm thickness, 0.75 mm gap, and 3 3 3 mm2 in-
plane resolution). Within each stage all acquisition param-
eters were kept consistent across subjects and sessions.
All functional images were preprocessed and analyzed
with SPM12 (www.fil.ion.ucl.ac.uk/spm) following a same
pipeline. We controlled potential effects of acquisition
sequences by including sequence as a between-subject fac-
tor in the group-level whole-brain analysis. The first 11
volumes were discarded to allow magnetization equilibra-
tion. The functional images were realigned to the mean
functional image, corrected for acquisition time difference,
normalized to the MNI space, smoothed with a Gaussian
kernel of 6-mm full-width half-maximum (FWHM), and
filtered with a 128 s high-pass filter.
A general linear model was built for each subject to
model the stop-signal trials and Go trials, separately for
successful and failed trials. The subject-level general linear
models convolved a design matrix with the canonical
hemodynamic response function. Six parameters of head
movement (translations and rotations) were integrated into
a single parameter, i.e., total displacement [Wilke, 2012], to
increase degrees of freedom and statistical power of the
subject-level model. Classical parameter estimation was
applied with a one-lag autoregressive model. We exam-
ined group differences on the “successful-stop > Go” con-
tract (stop-related activations) using a two-sample t test
(voxel-level p < 0.001, cluster-level p < 0.05 family-wise-
error-corrected for multiple comparisons).
The whole-brain analysis was followed by a region-of-
interest analysis to examine the effect of each drug on the
right inferior frontal gyrus (RIFG). The RIFG region was
defined as the intersection of the anatomical definition
(Automated Anatomical Labelling) and “successful-
stop > Go” contrast in control subjects, to provide anatom-
ically well defined, stop-related but unbiased regions-of-
interest for further analysis within patient subjects. For
each drug, parameter estimates for “successful-stop > Go”
were extracted and entered into a repeated-measures
ANCOVA controlled for age, disease severity, cognitive
status, levodopa equivalent dose, and plasma drug
concentration.
Construction of Predictive Models
The primary objective of this study is to discriminate
patient responders and nonresponders (binary classifica-
tion) against a benchmark of drug-induced behavioral
improvement using a support vector machine (SVM). We
conducted the analysis separately for each drug because
preclinical evidence suggests different psychopharmaco-
logical effects and neural correlates [Robbins, 2007].
Patients were defined as a responder if they showed an
SSRT reduction larger than 30% of the magnitude of Par-
kinson’s deficit in SSRT after drug versus placebo (the
principal benchmark). This definition balanced the size of
drug effect and the rate of patients considered as
responders. When the benchmark is too high (e.g., com-
plete resolution of Parkinson’s deficit), the model may
only enable the recognition of a small group of patients
who benefit most from the drug (e.g., 18–26% of the
patient cohort, see Supporting Information, Fig. S1). When
the benchmark is too low (e.g., behavioral improvement
of any size), the model will not be able to distinguish a
“meaningful” behavioral improvement from noise. In set-
ting the principal benchmark, we note that it was compa-
rable in scale to typical outcomes of chronic dopaminergic
treatments of motor symptoms and those of serotonergic/
noradrenergic treatments on affective symptoms [Fahn
et al., 2004; Wermuth and Group, 1998; Wiles et al., 2012].
Nevertheless, to assess the robustness of our method to
variations in the benchmark, we repeated the analysis
against a range of alternative benchmarks from 10% to
50% behavioral improvement, on a group scale and on an
individual scale (see Results and Supporting Information).
The analysis was implemented using the open-source
LIBSVM toolbox [Chang and Lin, 2011]. The binary classi-
fier used a radial basis function kernel [K, Eq. (1)] with
two parameters, the cost function C (the cost of misclassi-
fying data points) and kernel parameter c,
K xi; xj
 
5 exp 2gkxi- xjk2
 
;g > 0 (1)
We constructed two models for each drug: (1) a clinical
predictive model that used demographic (age, sex), clini-
cal (disease severity, cognitive status, levodopa equivalent
dose), and/or diffusion-weighted imaging measures (frac-
tional anisotropy, mean diffusivity) to predict the effect of
drug on behavior (e.g., SSRT-atomoxetine minus SSRT-pla-
cebo); and (2) a mechanistic model that explained the
behavioral change in terms of activation changes in the
RIFG, pre-SMA, caudate nucleus, and putamen on suc-
cessful stop-signal trials (e.g., activation-atomoxetine
minus activation-placebo). These regions were selected
because they play crucial roles in response inhibition [Lor-
enz et al., 2015; Yu et al., 2015; Zhang et al., 2015] and in
mediating the beneficial effect of atomoxetine [Ye et al.,
2015].
We assessed performance of the two models using
LOOCV, given the limited sample size. The LOOCV has a
smaller bias than other validation methods (e.g., split sam-
ple validation or twofold cross-validation) in estimating
the “true” prediction error in studies with small samples
because each observation has an equal chance to be in a
training set and a test set [Molinaro et al., 2005]. For each
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model, we reported mean prediction accuracy across mul-
tiple cross-validations.
Optimization of Parameters and Features
We optimized the model parameters (C, c) using a “grid-
search” algorithm recommended for LIBSVM [Chang and
Lin, 2011]. This algorithm searches across exponentially
growing sequences of C and c (e.g., C5 2210, 229.5,. . . 210;
c5 2210, 229.5,. . . 210) to maximize the cross-validation accu-
racy of a given model. We also searched for the best set of
features as follows. At each iteration, the algorithm
searched available features (e.g., n available features) for
the feature that increased the cross-validation accuracy
most when combined with features that have been selected
(e.g., m selected feature). The good feature was then moved
from the pool of available features to that of selected fea-
tures (resulting in n2 1 available features and m1 1
selected features). The algorithm terminated when adding
another feature no longer increased the cross-validation
accuracy, or when all features have been selected.
Statistical Significance of the Optimized Models
We assessed statistical significance of each model using
permutation tests (p < 0.05 Bonferroni-corrected for multi-
ple models). At each iteration, the class label (responder/
nonresponder) was randomized and new cross-validation
accuracy was calculated. A distribution of cross-validation
accuracy was generated from 5000 randomizations. The p-
value was defined as the rate of random models that
showed cross-validation accuracy larger than the real
model (Supporting Information, Fig. S2).
RESULTS
Behavioral Results
Compared to control subjects, patients under placebo
had longer SSRT (t 5 2.70, p < 0.01), longer Go reaction
times (t 5 3.03, p < 0.01), and more Go errors (t 5 3.19,
p<0.01). Citalopram, but not atomoxetine, reduced SSRT in
patients with more advanced disease (higher UPDRS-III
motor score; see Fig. 1 and Supporting Information, Tables
S1 and S2).
Functional Imaging Results
We first confirmed the previous fMRI findings using the
combined cohort (N 5 76) and replicated the previous
result in the subjects who had not participated in our pub-
lished studies (N 5 38; see Supporting Information, Figs.
S5 and S6).
The whole-brain analysis revealed group differences on
stop-related brain activation (p < 0.05 corrected; see Fig.
2A). Control subjects showed greater activation for success-
ful stop versus Go trials in the RIFG (peak in MNI coordi-
nates [44, 20, 4], t 5 10.93, 1760 voxels) and pre-SMA ([10,
12, 46], t 5 7.82, 892 voxels). The stop-related activations
were significantly reduced in patients under placebo com-
pared with controls in the RIFG ([44, 20, 22], t 5 6.21, 334
voxels) and pre-SMA ([6, 22, 40], t 5 4.69, 542 voxels).
The region-of-interest analysis revealed the effect of
each drug on stop-related activation (Fig. 2B). Both atom-
oxetine (F 5 5.62, p < 0.05) and citalopram (F 5 7.02,
p < 0.05) enhanced the RIFG activation (main effect of
drug), especially in patients with more advanced disease
(interaction of drug and disease severity: atomoxetine,
F 5 9.06, p 5 0.005; citalopram, F 5 12.42, p 5 0.001). We
present additional analyses of drug effects and results of
NoGo trials as Supporting Information.
Predictive Models for Atomoxetine and
Citalopram
Having confirmed previous findings in behavior and
imaging, we then constructed a “clinical” predictive model
and a “mechanistic” model for each drug against the prin-
cipal benchmark of 30% behavioral improvement (p < 0.05
corrected; see Table II), using the “grid-search” algorithm
(Fig. 3A).
Using the clinical predictive model, a 30% behavioral
improvement after atomoxetine was best predicted by the
combination of diffusion-weighted metrics of the anterior
internal capsule and levodopa equivalent dose. For citalo-
pram, the best predictive features included the fractional
anisotropy and mean diffusivity of the right anterior inter-
nal capsule, age, and cognitive status measured by the
mini mental state examination.
In the mechanistic models using post-hoc brain activa-
tions, the best predictive features against the principal
Figure 1.
Citalopram reduced the stop-signal reaction time (SSRT) in
patients with more advanced disease (higher UPDRS-III motor
subscale score). DSSRT indicates the change in SSRT after citalo-
pram versus placebo.
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benchmark were the drug-induced changes of activation in
the bilateral caudate nuclei and right pre-SMA for atomox-
etine, and the activation changes in the left caudate
nucleus, right putamen, and right pre-SMA for citalopram.
The models were similarly accurate to predict individual
patients’ responses to the drug against a range of alterna-
tive benchmarks (e.g., 10–50% behavioral improvement,
see Fig. 3B and Supporting Information, Tables S3 and S4).
The optimal models for the principal benchmark were also
robust as tested against other benchmarks (Fig. 3C). The
sensitivity and specificity of the models are presented in
the form of receiver operating characteristic curves as
shown in Supporting Information, Figure S7.
DISCUSSION
Response inhibition is an aspect of impulsivity that is
impaired in Parkinson’s disease but it is not usually
improved by levodopa or dopamine agonists. The limited
effect of selective dopaminergic drugs on response inhibi-
tion led us to investigate noradrenergic and serotonergic
agents as potential adjunctive treatments to regular anti-
parkinsonian medications. We confirmed the beneficial
effect of atomoxetine and citalopram on response inhibi-
tion in subgroups of patients with Parkinson’s disease,
rather than the whole group, and confirmed that the
change in behavior (after citalopram, see Fig. 1) and brain
activation (both drugs, see Fig. 2B) correlated with the
UPDRS measure of disease severity. Note, a groupwise
effect of atomoxetine has been observed on stopping accu-
racy and other behavioral indices of impulsivity in an
independent cohort of patients with Parkinson’s disease
[Kehagia et al., 2014]. In this study, the groupwise effect of
the drugs (on brain activation, see the bar plots of Fig. 2B)
should not be interpreted in isolation because it showed
a significant interaction with the disease severity
covariate (see the scatter plots of Fig. 2B). However, such
Figure 2.
Functional imaging results. (A) Control subjects showed greater
activations for successful stop versus go trials (stop-related brain
activations) in the right inferior frontal gyrus and presupplemen-
tary motor area. The stop-related activations were significantly
reduced in patients with Parkinson’s disease under placebo (PD-
PLA) compared to controls. Statistical parametric maps are
overlaid on a representative brain in the MNI space. Colors indi-
cate t values of one-sample or two-sample t tests as appropriate
(p < 0.05 corrected). (B) In the right inferior frontal gyrus, the
stop-related activation was enhanced after atomoxetine (ATO)
and citalopram (CIT) versus placebo (PLA; bar plots), especially
in patients with more advanced disease (higher UPDRS-III motor
score; scatter plots). The values of activation are mean parame-
ter estimates adjusted for clinical and demographic covariates.
DActivation indicates the change in the right inferior frontal
cortical activation after drug versus placebo, above the mean
improvement in activation. Error bars indicate standard errors.
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correlations are not sufficient for prospective trialists or
clinicians. Greater interest lies in the ability to predict indi-
vidual patients’ responses to these drugs and stratify inter-
ventions accordingly.
We therefore developed a clinical predictive model,
which identified potential responders with 77–79% accu-
racy using a binary classifier and simple measures avail-
able before treatment (e.g., age, cognitive status, levodopa
equivalent dose, and fractional anisotropy or mean diffu-
sivity measures taken from diffusion-weighted images; see
Table II and Supporting Information, Table S3). The princi-
ples and methods we used in this model are of direct rele-
vance to the design of future phase II/III clinical trials in
heterogeneous populations such as people with Parkin-
son’s disease.
Despite its correlation with the behavioral effect of cita-
lopram, the UPDRS measure was not a consistent feature
of the clinical model, possibly because the variance it
expresses was partially captured by the diffusion-
weighted imaging measures [Rae et al., 2012]. Although
the effects of both drugs are associated with common fron-
tostriatal circuits [Chamberlain et al., 2009; Del-Ben et al.,
2005; Macoveanu et al., 2013], we suggest that the distinct
clinical models for atomoxotine and citalopram reflect dif-
ferent roles of noradrenaline and serotonin in inhibitory
control [Eagle et al., 2008; Robbins, 2007]. In addition to
the clinical, demographic, and neuroanatomical factors we
have examined, genetic variations of neurotransmitter
transporters or microtubule-associated protein tau may
also play a role in treatment response [Dorszewska et al.,
2013; Nombela et al., 2014b; Whelan et al., 2012; Williams-
Gray et al., 2013].
We also present a post-hoc mechanistic model which
explained the behavioral effect with 85–88% accuracy in
terms of drug-induced changes in regional brain activa-
tion, either alone (see the “mechanistic” models in Table II
and Supporting Information, Table S4) or in conjunction
with clinical measures (see the “mixed” model in Support-
ing Information, Table S7). Whereas the clinical models for
Figure 3.
The clinical predictive model and mechanistic model were con-
structed separately for atomoxetine and citalopram, against the
principal benchmark of 30% behavioral improvement. (A) The
model parameters were optimized using a “grid-search” algo-
rithm, which searches across exponentially growing sequences
of C and g to maximize the cross-validation accuracy of a given
model. The illustrated example used data from the clinical model
of atomoxetine response. Colors indicate cross-validation accu-
racy values. (B) Cross-validation accuracy of the models that
were optimized for the principal benchmark and for alternative
benchmarks (e.g., 10–50% behavioral improvement, see Table II
and Supporting Information, Tables S3 and S4 for details). (C)
Robustness of the optimal models for the principal benchmark
was measured as cross-validation accuracy of the models when
tested against alternative benchmarks.
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atomoxetine and citalopram are clearly different, the
mechanistic models are convergent on the role of the stria-
tum bilaterally along with the pre-SMA and RIFG. A par-
simonious explanation of this convergence is that the
frontostriatal circuit integrates several pharmacological
processes, and expresses a final common pathway for
potential moderators of impulsivity in Parkinson’s disease.
In previous research [Ye et al., 2015], we included the
frontostriatal functional connectivity, in addition to the
RIFG activation, in a simple regression model to under-
stand the behavioral improvement after atomoxetine. With
a view to a more easily usable model, we did not include
such a functional connectivity measure which requires
more sophisticated analysis (e.g., pharmacophysiological
interactions) before building the classifier.
The effect of atomoxetine and citalopram is unlikely to
be mediated by directly increasing cortical dopamine
[Bymaster et al., 2002a,b). But an indirect contribution of
moderated dopamine neurotransmission is possible, given
the significance of the levodopa equivalent dose in the
clinical models. Candidate mechanisms for an indirect
effect of dopamine include postsynaptic interactions
between monoaminergic receptors [Albizu et al., 2011] and
reciprocal inhibitory interactions between monoaminergic
neurons in the midbrain [Guiard et al., 2008].
We also present clinical and mechanistic models opti-
mized with different feature inputs (see supplemental
results). These additional results showed the role and rela-
tive importance of each feature (e.g., whether prediction
accuracy changed when a particular feature was added
into or removed from the model). For example, the inclu-
sion of plasma drug concentration improved prediction
accuracy of the clinical model for atomoxetine response
(Supporting Information, Table S8), highlighting the
importance of measuring individual differences in drug
absorption (e.g., transit time and absorption in the gut
which is affected by additional autonomic deficits of idio-
pathic Parkinson’s disease) and metabolism (e.g., activity
of the cytochrome CYP enzyme family which plays a cru-
cial role in the metabolism of both atomoxetine and citalo-
pram). Like other recent psychopharmacological studies of
dopamine, serotonin, and noradrenaline, we did not
include measures of receptor occupancy using positron
emission tomography [Chowdhury et al., 2013; Costa
et al., 2013; van der Schaaf et al., 2013], but rather adopted
a simpler approach to incorporate individual differences
in plasma drug levels. The plasma drug concentration was
measured 2 h after the drug administration and immedi-
ately preceding the stop-signal task and functional imag-
ing, and used as a proxy for the next 20 min of functional
imaging. This single measure was sufficient to capture
some of the individual difference, although it will not
match the peak concentration of each patient (but it was
close to the maximal plasma concentration of both drugs
in the population, see [Chalon et al., 2003; Rocha et al.,
2007]).
LIMITATIONS
This study has potential limitations. We included
patients without clinically evident impulse control disor-
ders. However, 86% of patients with Parkinson’s disease
do not have impulse control disorders and yet manifest a
diverse array of impulsive behaviors on laboratory-based
neuropsychological tests and questionnaires regarding
everyday behaviors. Nevertheless, further studies would
be helpful to assess the use of atomoxetine and citalopram
in the important minority of patients with impulse control
disorders for whom reductions in dopaminergic medica-
tion may be poorly tolerated.
Another limitation is the extent to which effects on the
stop-signal task generalize to other complex impulsive
behaviors or clinically significant nonmotor symptoms.
The SSRT is not synonymous with impulsivity but it is a
well-established tool to study inhibitory control systems
across many neuropsychiatric disorders, providing a hom-
olog of animal paradigms. In Parkinson’s disease, it relates
to ecological and other laboratory tests of impulsivity in
humans [Kehagia et al., 2014; Nombela et al., 2014a). Stop-
ping efficiency is of course not equivalent to an assessment
of the quality of life, activities of daily living, or “everyday
TABLE II. Optimal clinical predictive and mechanistic models against the benchmark of 30% behavioral
improvement
Model type Drug Optimal features (C, c) Accuracy Significancea
Clinical Atomoxetine L mean diffusivity,b levodopa equivalent dose,
R fractional anisotropy, L fractional anisotropy
(25, 23) 76.5% p < 0.05
Clinical Citalopram R fractional anisotropy, age, R mean diffusivity,
MMSE
(210, 20.5) 79.4% p < 0.05
Mechanistic Atomoxetine R caudate nucleus, L caudate nucleus, R pre-SMA (1, 27) 85.3% p < 0.05
Mechanistic Citalopram L caudate nucleus, R putamen, R pre-SMA (26, 22) 85.3% p < 0.05
aStatistical significance measured as p-values from permutation tests (5000 randomizations, p < 0.05 corrected for multiple
comparisons).
bValues of fractional anisotropy and mean diffusivity were extracted from the anterior internal capsule. L, left; R, right; pre-SMA, pre-
supplementary motor area; MMSE, mimi mental state examination.
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impulsivity.” This study was exempted from clinical trials
status, as its focus was on the drugs’ effects on neurocog-
nitive systems, and the 30% improvement on stopping effi-
ciency is not a clinical index of improvement on quality of
life. However, we chose our definition of the benchmark
for responders so as to be comparable in scale to typical
outcomes of chronic dopaminergic treatments of motor
symptoms and serotonergic/noradrenergic treatments of
affective symptoms. For example, dopaminergic treatments
typically reduce UPDRS measures of disease severity by
30–40% [Fahn et al., 2004; Wermuth and Group, 1998],
while treatments with selective serotonin or noradrenaline
reuptake inhibitors typically reduce depression symptom
scores on the Beck Depression Inventory by 35% [Wiles
et al., 2012]. Nevertheless, further studies directed toward
clinical utility will have to incorporate clinical outcome
measures.
We investigated the behavioral efficacy of single-dose
atomoxetine and citalopram challenges. The acute and
chronic effects of citalopram are comparable in the context
of inhibitory control and reinforcement learning [Danet
et al., 2012], although not in depression [for a discussion,
see Ye et al., 2014]. Our use of single-dose atomoxetine is
in accordance with previous studies in boys with attention
deficit/hyperactivity disorder [Cubillo et al., 2014a,b).
Given the observed efficacy of acute doses, we propose
long-term treatment studies using an appropriate stratifi-
cation strategy to increase their power.
We built the predictive models on a relatively small
sample of patients with Parkinson’s disease, in part due to
the resources required for multimodal brain imaging that
was motivated by the need to cross-validate to preclinical
models of inhibitory frontostriatal systems. Given the sam-
ple size, we used LOOCV to estimate prediction error, as
this approach has been shown to be more accurate than
other validation approaches (e.g., a split-sample approach)
for small samples [Molinaro et al., 2005]. Nevertheless,
studies with larger patient samples are needed to for fur-
ther verifying the predictive model. While large and late-
stage clinical trials may use an alternative validation
method such as a priori split-sampling, other early stage
trials could benefit from the imaging-supported machine-
learning method we present.
One might argue that it would be more cost efficient to
simply try patients in clinic on the target drug. However,
the efficacy of the drugs would need to have been shown
in clinical trials, which are liable to be negative if the wide
individual variability in treatment response is not recog-
nized, or pretreatment information is not used to properly
stratify patients. Our inclusion of diffusion-weighted imag-
ing measures in the clinical model could also be chal-
lenged, as not all patients undergo brain imaging.
However, the diffusion-weighted measure we propose is
basic and suitable for automation from most clinical 3 T
MRI scanners (i.e., a simple measure in one region of
interest, not a complicated tract-based index). Moreover,
the cost of brain imaging can be considered against the
cost of the failure of unstratified clinical trials, the annual
cost of ineffective treatments (e.g., current local cost of a
National Health Service MRI equates to 2 months treat-
ment of 40 mg atomoxetine), and the risk of harm from
treating those in whom a negative response could be
predicted.
CONCLUSION
In conclusion, we have confirmed the potential benefi-
cial effect of atomoxetine and citalopram on response inhi-
bition in selected subgroups of patients with Parkinson’s
disease, building on a large body of comparative studies.
We found that a simple classifier can identify potential
responders with high accuracy, while recognizing the lack
of consensus on the threshold for response and the impor-
tant role of clinical outcome measures in chronic treatment
trials. The classification method is applicable not only to
Parkinson’s disease, but also more widely in the transla-
tion from preclinical studies to experimental medicine and
further toward stratified clinical trials, which is especially
relevant to drug development and early stage trials.
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